Abstract
Cisplatinum may prove to be a valuable agent for the elimination of diseased cells in the bone marrow of patients with neuroblastoma. In this study, we measured the efficacy of cisplatinum on human neuroblastoma cell lines and on normal human bone marrow progenitors, GM-CFC and CFU-F. Data indicate that the therapeutic index of cisplatinum is high. We set up an experimental model consisting of a mixture of human bone marrow and human neuroblastoma cells in order to confirm these preliminary results in purging conditions. Results indicate that cisplatinum exhibits a high and specific tumoricidal property and appears to be valid in bone marrow purging.
Highlights
Given the results obtained concerning NB cells in the mixture, we tried to fit those obtained for GM-CFC and CFU-F cells (Figures 2 and 3), in a range of a concentration below 1O gM which only covers the first decrease in survival of these cells
Our results show that CDDP could be an efficient purging agent for NB in ABMT purging conditions
In order to evaluate the differential susceptibility of tumour cells according to their concentration in bone marrow mixtures, we carried out another set of experiments using mixtures containing 1% of NB cells and similar results were obtained
Summary
For the culture of bone marrow and tumour cell mixtures, MEMHITES medium was used (Carney et al, 1981). This defined medium consists of products dissolved in MEM medium at the following final concentrations: 10-8M hydrocortisone, 5 .g ml-' insulin, 1I 00 g ml-' human transferrin, 10-8M 17 P-oestradiol, 3 x Io-' M sodium selenite. Two human neuroblastoma cell lines, SK-N-SH and SK-N-AS, were kindly provided by Dr Helson (Sloan Kettering Institute, New York). Regression analysis was used in order to fit the proportion of surviving cells as a function of drug concentration in the IGR-N-835-bone marrow cell mixture, GM-CFC and CFU-F. We applied two types of dose-response models, a linear and an exponential one
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
